Abbott India (ABBOTINDIA) Fundamentals 2026 — P/E 39.6x, Revenue Analysis | SniperIQ
Abbott India (ABBOTINDIA) is a India-listed Healthcare company in Drug Manufacturers - General with a market capitalization of ₹61,460 Crore, trading at ₹28898.60 on the BSE. This SniperIQ fundamentals page covers Abbott India's valuation (P/E 39.6x, P/B 12.9x), profitability (net margin 22.4%), revenue (₹6,929 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Abbott India's market cap?
Abbott India (ABBOTINDIA) has a market capitalization of approximately ₹61,460 Crore, trading at ₹28898.60 on the BSE. Market cap moves with the live share price.
What is Abbott India's P/E ratio?
Abbott India's trailing twelve-month P/E ratio is 39.6x, with a price-to-book (P/B) of 12.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Abbott India?
Abbott India runs a net profit margin of 22.4%, a gross margin of 44.3%, and an operating margin of 26.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Abbott India generate?
Abbott India reported revenue of ₹6,929 Crore for fiscal year 2026, with net income of ₹1,552 Crore and earnings per share (EPS) of 730.37. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Abbott India pay a dividend?
Abbott India offers a trailing dividend yield of about 1.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Abbott India financially healthy?
Abbott India carries a debt-to-equity ratio of 0.04x and a current ratio of 2.55x, with a market beta of -0.00. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Abbott India a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Abbott India (ABBOTINDIA) the key facts are: market cap ₹61,460 Crore, P/E 39.6x, revenue ₹6,929 Crore, 52-week range 26560.05-35921.55. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Abbott India's full fundamentals live
Get Abbott India's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.